Arrow Immune
UEI: F8YDZ5YCHDA6
• CAGE: 980A5
Overview
Awardee Type
Parent
Federal Capability Statement
Arrow Immune, Inc. is developing next-generation biologics for immuno-oncology in solid tumors. The company is developing protein engineering to retain immunotherapeutic molecules within tumors. The company has developed approaches to mask these compounds such that they are inactive in the periphery yet are activated within the tumor, to limit immune-related adverse events and widen the therapeutic window.
Keywords
Immuno-oncology, Immunotherapy, Oncology, Immunology, Research and Development, Drug Development, Clinical Trials, Life Sciences, Biotechnology, Immunoengineering, Pharmaceuticals, Medicine
Quality Assurance Certifications
ISO-9000 Series
Headquarters
Chicago, IL
United States
United States
Federal recipient
ARROW IMMUNE, INC.
(UEI F8YDZ5YCHDA6, CAGE 980A5)
is headquartered in Chicago IL.
Its primary registered NAICS is 541714 Research and Development in Biotechnology (except Nanobiotechnology).
The corporation
was founded in September 2018 and
federally registered in
December 2021.
Federal Registration and Certifications
Legal Name
ARROW IMMUNE, INC.
Division Name
ARROW IMMUNE, INC
UEI
F8YDZ5YCHDA6
CAGE Code
980A5
SBA Certifications
None
Self Certifications
Self-Certified Small Disadvantaged Business
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
Sept. 6, 2018
Initial Registration
Dec. 15, 2021
Last Registration
Jan. 14, 2023
Registration Activation
Dec. 22, 2021
Registration Expiration
Jan. 14, 2023
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
State of Incorporation
DE
Country of Incorporation
USA
Employees
<500
Reported NAICS
Accepts Credit Cards
No